Guidant CRT-D Non-Ischemic Label Expansion Endorsed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Guidant cardiac resynchronization therapy defibrillators reduce heart failure mortality and symptoms for both ischemic and non-ischemic patients but may not prevent hospitalizations, according to FDA's Circulatory System Devices Panel